


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9531520/publications.pdf Version: 2024-02-01



MA77A F

#	Article	IF	CITATIONS
1	Meningioma. Critical Reviews in Oncology/Hematology, 2008, 67, 153-171.	2.0	301
2	Ependymoma. Critical Reviews in Oncology/Hematology, 2007, 63, 81-89.	2.0	147
3	Temozolomide as salvage treatment in primary brain lymphomas. British Journal of Cancer, 2007, 96, 864-867.	2.9	135
4	Central nervous system gliomas. Critical Reviews in Oncology/Hematology, 2017, 113, 213-234.	2.0	109
5	Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. Journal of Neuro-Oncology, 2016, 126, 519-525.	1.4	105
6	Carbohydrate antigen 19â€9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer, 2009, 115, 2630-2639.	2.0	104
7	Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. European Journal of Endocrinology, 2010, 163, 843-851.	1.9	86
8	Anaplastic astrocytoma in adults. Critical Reviews in Oncology/Hematology, 2007, 63, 72-80.	2.0	67
9	The role of CXCR4 in highly malignant human gliomas biology: Current knowledge and future directions. Glia, 2014, 62, 1015-1023.	2.5	53
10	Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 691-697.	3.7	50
11	Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. Cancer Treatment Reviews, 2019, 72, 1-6.	3.4	46
12	Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel–Lindau related hemangioblastomas of the central nervous system. Critical Reviews in Oncology/Hematology, 2013, 86, 69-84.	2.0	40
13	Primary central nervous system lymphomas: Salvage treatment after failure to high-dose methotrexate. Cancer Letters, 2007, 258, 165-170.	3.2	32
14	Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2009, 64, 1253-1259.	1.1	32
15	Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemotherapy and Pharmacology, 2016, 77, 115-120.	1.1	31
16	PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen as Second-Line Therapy in Patients With Progressive or Recurrent Pancreatic Cancer After Gemcitabine-Containing Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 145-150.	0.6	21
17	A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2008, 62, 673-678.	1.1	18
18	Second-line therapy in advanced biliary tract cancer: What should be the standard?. Critical Reviews in Oncology/Hematology, 2013, 88, 368-374.	2.0	18

Mazza E

#	Article	IF	CITATIONS
19	Breast metastases from oligodendroglioma: An unusual extraneural spread in two young women and a review of the literature. Critical Reviews in Oncology/Hematology, 2013, 88, 564-572.	2.0	10
20	Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2020, 85, 641-650.	1.1	8
21	Novel therapeutics in adult malignant brain gliomas. Expert Opinion on Investigational Drugs, 2005, 14, 643-658.	1.9	4
22	Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients. Cancer Chemotherapy and Pharmacology, 2021, 87, 95-101.	1.1	3
23	Weekly Epirubicin as Salvage Therapy in Patients with Gemcitabine-Resistant Advanced Pancreatic Cancers. Journal of Chemotherapy, 2009, 21, 698-700.	0.7	2
24	Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. Digestive and Liver Disease, 2021, 53, 117-121.	0.4	1
25	Erratum to "Time course of hypothalamic-pituitary deficiency in adults receiving cranial radiotherapy for primary extrasellar brain tumors―[Radiother. Oncol. 99 (2011) 23–28]. Radiotherapy and Oncology, 2012, 104, 408.	0.3	0